An independent and external validation of QRISK2 cardiovascular disease risk score: A prospective open cohort study

BMJ (Online)

Volumn 340, Issue 7758, 2010, Pages 1231-

  Collins, Gary S ^a   Altman, Douglas G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; ETHNICITY; FEMALE; GENERAL PRACTICE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORBIDITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QRISK1 SCORING SYSTEM; QRISK2 SCORING SYSTEM; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; SOCIAL ISOLATION; STROKE; TRANSIENT ISCHEMIC ATTACK; UNITED KINGDOM; VALIDATION STUDY;

ADULT; AGED; CARDIOVASCULAR DISEASES; FAMILY PRACTICE; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 77953707407     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c2442     Document Type: Article

References (38)

1. Cooper A, O'Flynn N, on behalf of the Guideline Development Group. Risk assessment and lipid assessment for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. BMJ 2008;336:1246-8.
2. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MSV, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408-16.
3. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121(1 pt 2):293-8.
4. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 2007;297:611-9.
5. ConroyRM,Pyörälä K, Fitzgerald AP, Sans S, Menotti A, de Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
6. WoodwardM, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score fromthe Scottish Heart Health Extended Cohort (SHHEC). Heart 2007;93:172-6.
7. Mayor S. Doctors no longer have to use Framingham equation to assess heart disease risk, NICE says. BMJ 2010;340:c1774.
8. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136.
9. Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ 2009;339:b2584.
10. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart 2008;94:34-9.
11. Collins GS, Altman DG. Report to the Department of Health: independent validation of QRISK on the THIN database. University of Oxford, 2008.
12. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:a332.
13. Royston P, Sauerbrei W. Multivariable modelling: a pragmatic approach to fractional polynomials for continuous variables. Wiley, 2008.
14. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000;19:453-73.
15. Altman DG, Vergouwe Y, Royston P, Moons KGM. Prognosis and prognostic research: validating a prognostic model. BMJ 2009;338:b605.
16. McGeechan K, Macaskill P, Irwig L, Liew G, Wong TY. Assessing new biomarkers and predictive models for use in clinical practice: a clinician's guide. Arch Intern Med 2008;168:2304-10.
17. Omar RZ, Ambler G, Royston P, Eliahoo J, Taylor KM. Cardiac surgery risk modeling for mortality: a review of current practice and suggestions for improvement. Ann Thorac Surg 2004;77:2232-7. (Pubitemid 38686640)
18. Mallett S, Royston P, Waters R, Dutton S, Altman DG. Reporting performance of prognostic models in cancer: a review. BMC Med 2010;8:21.
19. Mallett S, Royston P, Dutton S, Waters R, Altman DG. Reporting methods in studies developing prognostic models in cancer: a review. BMC Med 2010;8:20.
20. Hemmingway H, Riley RD, Altman DG. Ten steps towards improving prognosis research. BMJ 2009;339:b4184.
21. NICE Guideline. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (2008). Available at http:// guidance.nice.org.uk/CG67 (accessed 8 Oct 2009).
22. Janssen KJM, Vergouwe Y, Donders ART, Harrell FE, Chen Q, Grobbee DE, et al. Dealing with missing predictor values when applying clinical prediction models. Clin Chem 2009;55:994-1001.
23. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999;8:3-15.
24. Graf E, Schmoor C, Sauerbrei W, Schumacher M. Assessment and comparison of prognostic classification schemes for survival data. Stat Med 1999;18:2529-45. (Pubitemid 29423514)
25. Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med 2004;23:723-48.
26. Royston P. Explained variation for survival models. Stata Journal 2006;6:1-14.
27. Marshall R. Cardiovascular risk can be represented by scaled rectangle diagrams. J Clin Epidemiol 2009;62:998-1000.
28. Janes H, Pepe MS, Gu W. Assessing the value of risk predictions by using risk stratification tables. Ann InternMed 2008;149:751-60.
29. R Development Core Team. R: a language and environment for statistical computing. www.R-project.org.
30. Jackson R. Cardiovascular risk prediction: are we there yet? Heart 2008;94:1-3.
31. Jackson R, Marshall R, Kerr AJ, Riddell T, Wells S. QRISK or Framingham for predicting cardiovascular risk? BMJ 2009;339:b2673.
32. Liew SM, Glasziou P. QRISK validation and evaluation. QRISK may be less useful. BMJ 2009;339:b3485.
33. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk. A review for clinicians. J AmColl Cardiol 2009;54:1209-27.
34. Tsang VT, Brown KL, Synnergren MJ, Kang N, de Leval MR, Gallivan S, et al. Monitoring risk-adjusted outcomes in congenital heart surgery: does the appropriateness of a risk model change with time? Ann Thorac Surg 2009;87:584-8.
35. Clark TG, Altman DG. Developing a prognosticmodel in the presence of missing data: an ovarian cancer case study. J Clin Epidemiol 2003;56:28-37.
36. Janssen KJM, Vergouwe Y, Donders ART, Harrell FE, Chen Q, Grobbee DE, et al. Dealing with missing predictor values when applying clinical prediction models. Clin Chem 2009;55:994-1001.
37. Marshall A, Altman DG, Holder R, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Meth 2009;9:57.
38. Vergouwe Y, Royston P, Moons KGM, Altman DG. Development and validation of a prediction model with missing predictor data: a practical approach. J Clin Epidemiol 2010;63:205-14.